Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising cocktail targets tough lung cancer

NCT ID NCT05142696

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 5 times

Summary

This study tests a radioactive drug called Lutathera added to standard chemotherapy and immunotherapy for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to find a safe dose and see if the combination helps people live longer. About 24 participants will receive the treatment, and researchers will monitor side effects and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lutathera (lutetium Lu 177 dotatate) plus carboplatin, etoposide, and atezolizumab
What this could lead to
If successful, this could offer a new treatment option that improves survival for people with an aggressive type of lung cancer.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply to everyone. The combination may cause serious side effects or not work better than current therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

55 people

The number who actually took part.

Started

Jul 2022

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Participant is \>= 18 years on the day of signing informed consent form * Histologically or cytologically confirmed ES-SCLC * Presence of measurable disease * No prior systemic treatment for ES-SCLC (except the first cycle of chemotherapy with or without atezolizumab of the induction period * ECOG status =\< 1 * Provision of tumor tissue to support exploratory biomarker analysis * Life expectancy of \>= 6 months Key Exclusion Criteria: * Participant has received prior therapy with an antibody or drug against immune checkpoint pathways * Active autoimmune diseases or history of autoimmune diseases that may relapse * Severe chronic or active infections (including active tuberculosis, HBV, or HCV infection) requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks before Cycle 1 Day 1 * Any major surgical procedure requiring general anesthesia =\< 28 days before Cycle 1 Day 1 * History or current diagnosis of electrocardiogram (ECG) abnormalities indicating significant risk of safety for participants participating in the study * Known hypersensitivity to the active substances or any of the excipients of the study drugs * Concurrent participation in another therapeutic clinical study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extensive-stage small-cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extensive-stage small-cell lung cancer

Contacts and locations

Locations

  • AdventHealth

    Orlando, Florida, 32804, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Hackensack University Medical Ctr

    Hackensack, New Jersey, 07601, United States

  • Novartis Investigative Site

    Vienna, 1090, Austria

  • Novartis Investigative Site

    Montreal, Quebec, H2X 1R9, Canada

  • Novartis Investigative Site

    Beijing, 100036, China

  • Novartis Investigative Site

    Shanghai, 200032, China

  • Novartis Investigative Site

    Olomouc, 779 00, Czechia

  • Novartis Investigative Site

    Lille, 59000, France

  • Novartis Investigative Site

    Marseille, 13885, France

  • Novartis Investigative Site

    Montpellier, 34298, France

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Beersheba, 8457108, Israel

  • Novartis Investigative Site

    Ramat Gan, 5265601, Israel

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Singapore, 168583, Singapore

  • Novartis Investigative Site

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    Madrid, 28009, Spain

  • Novartis Investigative Site

    Madrid, 28040, Spain

  • Novartis Investigative Site

    Málaga, 29010, Spain

  • Novartis Investigative Site

    Guildford, Surrey, GU2 7XX, United Kingdom

  • St Louis University

    St Louis, Missouri, 63104, United States

  • University Cancer and Blood Center LLC

    Athens, Georgia, 30607, United States

  • University Hospitals Of Cleveland

    Cleveland, Ohio, 44106, United States

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.